Cytyc Corporation Announces $150.0 Million Senior Unsecured Credit Facility

The Credit Agreement provides for a $150.0 million seniorunsecured revolving credit facility to the Company for generalcorporate purposes. Within the $150.0 million commitment aresub-limits for letters of credit and borrowings in other than the U.S.currency. The Company has the ability to increase borrowings under theCredit Agreement by up to an additional $150.0 million at its optionupon satisfaction of certain conditions.

The Company is required under the Credit Agreement to comply withmaximum leverage and minimum interest coverage ratios. In addition,the Credit Agreement contains other standard affirmative and negativecovenants and conditions of default.

"Although no immediate plans to use the credit facility isanticipated, this Agreement provides the Company with the maximumfinancial flexibility to continue to grow our business while takingadvantage of the favorable conditions in the credit markets," saidPatrick Sullivan, chairman, president, and chief executive officer.

Cytyc Corporation is a leading women's health company thatdesigns, develops, manufactures, and markets innovative and clinicallyeffective products for cervical cancer screening, breast cancer riskassessment, treatment of excessive menstrual bleeding, and treatmentof breast cancer.

Cytyc is traded on The Nasdaq Stock Market under the symbol CYTC.Cytyc is a registered trademark of Cytyc Corporation.

Forward-looking statements in this press release are made pursuantto the provisions of Section 21E of the Securities Exchange Act of1934. Investors are cautioned that statements in this press releasewhich are not strictly historical statements, including, withoutlimitation, statements relating to Cytyc's future financial condition,operating results and economic performance, and management'sexpectations regarding key customer relationships, future growthopportunities, product acceptance and business strategy, constituteforward-looking statements. These statements are based on currentexpectations, forecasts and assumptions that are subject to risks anduncertainties, which could cause actual outcomes and results to differmaterially from those statements. Risks and uncertainties include,among others, dependence on key personnel and customers as well asreliance on proprietary technology, uncertainty of product developmentefforts and product acceptance, management of growth and productdiversification, entry into new market segments domestically and newmarkets internationally, risks associated with litigation, theeffective integration of acquired businesses and technologies,competition and competitive pricing pressures, risks associated withthe FDA regulatory approval processes and healthcare reimbursementpolicies in the United States and abroad, introduction of technologiesthat are disruptive to Cytyc's business and operations, the impact ofnew accounting requirements and governmental rules and regulations, aswell as other risks detailed in Cytyc's filings with the Securitiesand Exchange Commission, including those under the heading "RiskFactors" in its 2005 Annual Report on Form 10-K and its most recentQuarterly Report on Form 10-Q filed with the Commission. Cytyccautions readers not to place undue reliance on any suchforward-looking statements, which speak only as of the date they weremade. Cytyc disclaims any obligation to publicly update or revise anysuch statements to reflect any change in its expectations or events,conditions, or circumstances on which any such statements may bebased, or that may affect the likelihood that actual results willdiffer from those set forth in the forward-looking statements.